TABLE 2.

Predictors of response to ustekinumab in pediatric inflammatory bowel disease

Clinical factor	Steroid-free remission at week 52, % n = 52	P value	Clinical remission at week 52, % n = 52	P value	Biomarker remission at week 52, % n = 52	P value
Any large bowel disease	55	0.488	64	1.000	62	0.729
Large bowel disease only	57	0.879	65	0.982	70	0.416
Anti-TNF failure	50	0.032	60	0.136	57	0.072
Age <10 at diagnosis	57	0.947	71	0.451	67	0.693
Psoriasiform dermatitis	62	0.746	62	0.736	62	0.868
IMM at UST start	54	0.746	69	1.000	69	0.746
Steroids at UST start	61	0.634	68	0.686	64	0.894
CD	62	0.500	67	0.723	62	0.729
UC/IBDU	50	0.500	60	0.723	70	0.729
Vedolizumab failure	47	0.253	68	0.727	63	0.457
Dose escalation	63	0.336	70	0.414	63	0.982
Last Anti-TNF >30 d from UST start*	52	1.000	64	0.446	61	0.462
Last Anti-TNF >90 d from UST start*	45	0.537	65	0.491	60	0.721
Anti-TNF before Vedolizumab†	44	0.582	69	1.000	69	1.000

CD = Crohn disease; d = days; IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unspecified; IMM = immunomodulator; TNF = tumor necrosis factor; UC = ulcerative colitis; UST = ustekinumab; VDZ = vedolizumab.

^*n = 42, accounting for only those patients exposed to anti-TNF.

^†n = 19, accounting for only those patients exposed to anti-TNF and VDZ.